Antipsychotics for acute treatment of first episode schizophrenia

Creative-Tail-medicine.svg

Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode schizophrenia.

[read the full story...]

Antipsychotic efficacy measured by real-world observational study

telescope-1082091_640

Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics.

[read the full story...]

Schizophrenia, antipsychotics and quality of life: measuring the important things

photo-1436124396594-54d90bf69c66

Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that second generation antipsychotics may be superior to first generation antipsychotics in terms of improving quality of life for people with schizophrenia.

[read the full story...]

Cochrane find no evidence for as required PRN medication for mental health inpatients

4711660113_49676b8c32_b

John Baker summarises an updated Cochrane review on ‘as required’ PRN medication regimens for seriously mentally ill people in hospital, which finds no randomised controlled trials that support this widely used intervention.

[read the full story...]

Paliperidone Palmitate is no better than Haloperidol Decanoate at preventing relapse or controlling psychotic symptoms

shutterstock_150559310

Alex Langford summarises a relatively large and pragmatic study, which provides firm evidence that the newer antipsychotic, Paliperidone, is no better at preventing relapse or controlling psychotic symptoms than its decades-old comparator, Haloperidol.

[read the full story...]

Cochrane review finds that haloperidol is an effective antipsychotic, but its side effects can be problematic

shutterstock_108676748

Schizophrenia is a serious disorder characterised by delusions (including paranoid beliefs and hallucinations) and other symptoms such as blunted affect and reduced motivation. While relatively uncommon (lifetime prevalence is less than 1%), it is associated with serious social impairment (e.g., unemployment, homelessness), which in turn can result in physical health problems. As a result, the [read the full story…]

Cochrane review finds quetiapine is equivalent in efficacy to typical antipsychotics and possibly causes fewer side effects

Antipsychotic medication is the standard treatment for schizophrenia and psychosis in the UK.  Given that psychosis is commonly a chronic condition and therefore that medication used to treat it often needs to be taken for several years, getting the medication “right” is important. As I mentioned in my first blog post for the Mental Elf, [read the full story…]